OUR TEAM
Daniel Jacobs, PhD, MPH
Founder & Managing Partner
Daniel founded Pathway Bioventures in 2018 to accelerate the growth of groundbreaking early-stage life sciences companies. He leads Pathway’s operations and investment activities including the identification of new opportunities, diligence, and portfolio company support. A cancer researcher by training, Daniel has expertise in cancer epidemiology, genomics, and RNA therapeutics, having authored or co-authored over 25 peer-reviewed scientific articles and book chapters. He has served as a Board Observer for Modifi Bio (acquired by Merck), Biograph55, and miRecule and as an Entrepreneur-in-Residence at Yale Ventures. Daniel holds an MPH and PhD from Yale University and received post-doctoral training at Baylor College of Medicine.
Matt Martin, PhD, MBA
Partner
As a Partner at Pathway Bioventures, Matt seeks out opportunities where investment can efficiently create significant value and bring new scientific discoveries to the clinic and improve patients' lives. His work builds on 15 years of management experience from roles in universities, startups, and early-stage investment groups. Additionally, Matt has been an early employee or co-founder of several therapeutics companies, and is the founding CEO of Saros Therapeutics today. Matt was trained with a PhD in Physics from Carnegie Mellon University and continued his research with a post-doctoral position at Los Alamos National Labs. He also earned an MBA from the University of Chicago Booth School of Business with concentrations in strategy, finance, and entrepreneurship.
Jacob Segil, PhD
Venture Partner
Jacob is a Research Professor in Mechanical Engineering as well as the Managing Director of the Center for Translational Research at University of Colorado Boulder. He researches neural interfaces, prosthetic devices, and artificial sensory feedback systems. Jacob has founded three companies focusing on medical device development and serves as CEO of neural engineering company Afference.
marta new, PhD, mba
Strategic Advisor
Marta is a founder and CEO of Radyus Research, a collaborative research organization specializing in preclinical drug development. She is an experienced drug developer and biotech investor having held positions at Agent Capital, Baxter Ventures, and Baxalta Ventures. Marta received her PhD in immunology and microbiology from the University of Illinois at Chicago and an MBA from Northwestern University.
DAVID HARDWICKE, MS
Investment Consultant
David is a biotechnology professional with a background in technology commercialization, program management, and drug development with prior positions at Novartis Gene Therapies and NK-cell therapy developer ONK Therapeutics. As a consultant with Pathway Bioventures, David works on new investment opportunities and has contributed to our investments in gene editing, RNA therapeutics, and novel cancer therapies.